Dentsply Sirona to Participate in Upcoming Investor Conferences
Get Alerts XRAY Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 5.7%
EPS Growth %: -36.0%
Join SI Premium – FREE
CHARLOTTE, N.C., Nov. 11, 2022 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona”) (Nasdaq: XRAY) today announced its participation at upcoming conferences.
- Jefferies 13th Annual London Healthcare Conference on November 17, 2022 at 12:20 pm GMT (7:20 am ET)
- Evercore ISI 5th Annual HealthCONx Conference on December 1, 2022 at 1:00 pm ET
Investors and other interested parties will be able to access a live webcast of the presentations and webcast replays by visiting the Investors section of the Dentsply Sirona website at https://investor.dentsplysirona.com.
About Dentsply Sirona
Dentsply Sirona is the world’s largest manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including dental and oral health products as well as other consumable medical devices under a strong portfolio of world class brands. Dentsply Sirona’s products provide innovative, high-quality and effective solutions to advance patient care and deliver better and safer dental care. Dentsply Sirona’s headquarters is located in Charlotte, North Carolina. The Company’s shares are listed in the United States on Nasdaq under the symbol XRAY. Visit www.dentsplysirona.com for more information about Dentsply Sirona and its products.
Contact Information
Investors:Andrea DaleyVP, Investor Relations+1-704-805-1293[email protected]
Source: DENTSPLY SIRONA Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Computer Modelling Group Announces Annual General Meeting Voting Results
- Axe Compute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- FDA Approves Isembyld (apitegromab-mstn), the First and Only Muscle-Targeted Therapy for Spinal Muscular Atrophy, Marking a New Milestone in SMA Treatment
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share